Last reviewed · How we verify
Incretin Effect
The incretin effect enhances insulin secretion in response to oral glucose intake by stimulating incretin hormones (GLP-1 and GIP) released from the intestine.
The incretin effect enhances insulin secretion in response to oral glucose intake by stimulating incretin hormones (GLP-1 and GIP) released from the intestine. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Incretin Effect |
|---|---|
| Sponsor | University of Campania Luigi Vanvitelli |
| Drug class | Incretin-based therapy (mechanism class) |
| Target | GLP-1 receptor and/or GIP receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
When glucose is consumed orally, intestinal L-cells release incretin hormones (glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]), which account for 50-70% of the postprandial insulin secretion. These hormones bind to their respective receptors on pancreatic beta cells, triggering glucose-dependent insulin release. This physiological mechanism is leveraged therapeutically by incretin-based drugs to improve glycemic control in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Hypoglycemia
Key clinical trials
- The Effect of Adiposity on Muscle and Microvascular Function in HFpEF
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
- A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese (PHASE1)
- Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes (PHASE4)
- Nutrition+: Effect of a High-Protein Diabetes Formula on Body Composition in Type 2 Diabetes Patients Treated With Incretin Mimetics (NA)
- The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 Diabetes (NA)
- Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA) (NA)
- Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Incretin Effect CI brief — competitive landscape report
- Incretin Effect updates RSS · CI watch RSS
- University of Campania Luigi Vanvitelli portfolio CI